KRAS and neoplasm: Evaluation of outcomes in patients with wild-type RAS tumours (i.e., wild-type for KRAS and NRAS, exons 2, 3, and 4) by extended RAS analysis have shown numerically improved survival relative to patients with wild-type KRAS exon 2 tumours in the first-line (PRIME) (Douillard et al, 2013) and second-line (20050181) (Peeters et al, 2015) settings.